Ftse Mib
33.276,91
1,12%
DAX
18.107,15
0,18%
S&P 500
5.473,23
0,77%
NASDAQ
0,00
0,00%
Bitcoin
65.278,37
-1,82%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Karuna Therapeutics Inc (KRTX) Karuna Therapeutics Inc (KRTX) Notizie

KRTX

Karuna Therapeutics (KRTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KRTX
DataOraFonteTitoloSimboloCompagnia
11/03/202422:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
08/03/202423:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
01/03/202412:02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRTXKaruna Therapeutics Inc
01/03/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRTXKaruna Therapeutics Inc
22/02/202412:39Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KRTXKaruna Therapeutics Inc
22/02/202412:30Business WireKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateNASDAQ:KRTXKaruna Therapeutics Inc
14/02/202416:04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KRTXKaruna Therapeutics Inc
05/02/202422:12Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:KRTXKaruna Therapeutics Inc
22/01/202412:05Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:KRTXKaruna Therapeutics Inc
08/01/202416:06PR Newswire (US)Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law FirmNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202321:30PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.NASDAQ:KRTXKaruna Therapeutics Inc
22/12/202317:15Dow Jones NewsTrending: Bristol Myers to Buy Karuna Therapeutics for $14 BillionNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202313:05Business WireBristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna TherapeuticsNASDAQ:KRTXKaruna Therapeutics Inc
15/12/202300:30Business WireKaruna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in SchizophreniaNASDAQ:KRTXKaruna Therapeutics Inc
29/11/202316:17Business WirePureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaNASDAQ:KRTXKaruna Therapeutics Inc
29/11/202313:13Dow Jones NewsKaruna Therapeutics Gets FDA Acceptance for KarXT NDANASDAQ:KRTXKaruna Therapeutics Inc
29/11/202312:30Business WireKaruna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaNASDAQ:KRTXKaruna Therapeutics Inc
16/11/202322:01Business WireKaruna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in SchizophreniaNASDAQ:KRTXKaruna Therapeutics Inc
02/11/202311:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRTXKaruna Therapeutics Inc
02/11/202311:30Business WireKaruna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesNASDAQ:KRTXKaruna Therapeutics Inc
01/11/202311:45Business WireKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute CongressNASDAQ:KRTXKaruna Therapeutics Inc
01/11/202311:30Business WireKaruna Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:KRTXKaruna Therapeutics Inc
19/10/202312:30Business WireKaruna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023NASDAQ:KRTXKaruna Therapeutics Inc
04/10/202312:30Business WireKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) CongressNASDAQ:KRTXKaruna Therapeutics Inc
03/10/202323:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
28/09/202312:30Business WireKaruna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of SchizophreniaNASDAQ:KRTXKaruna Therapeutics Inc
03/08/202312:32Business WireKaruna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business UpdatesNASDAQ:KRTXKaruna Therapeutics Inc
03/08/202312:30Business WireKaruna Therapeutics Announces Leadership AppointmentsNASDAQ:KRTXKaruna Therapeutics Inc
20/07/202312:30Business WireKaruna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023NASDAQ:KRTXKaruna Therapeutics Inc
22/06/202322:19Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KRTXKaruna Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KRTX

La tua Cronologia

NASDAQ
PFIS
Peoples Financial Services
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network